Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Cambium Bio Ltd

CMB.AX ✓ COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.25

▲ +0.00%

Market Cap $7.47M · Vol 2.87K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$7.47M

Micro Cap

Div Yield

N/A

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

0.00

Momentum

Beta

-0.19

vs Market

52W High

$0.42

39.93% below

52W Low

$0.24

9.89% above

Volume

2.87K

Avg 864

P/B

2.09

Price-to-book

ROE

N/A

Return on equity

Free Float

12.31%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Cambium Bio Ltd (CMB.AX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CMB.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-12.20%

-11.11%

-7.69%

-35.71%

YTD

-23.40%

-2.70%

-51.36%

-95.66%

Financials & Valuation

TTM · Annual

Total Revenue	$440.90K
Net Income	$-2,529,511.00
Revenue Growth (YoY)	+17.77%
Gross Margin	70.04%
Operating Margin	-620.57%
Net Profit Margin	-573.72%
ROE	N/A
ROA · ROIC	-85.96% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	5.73
P/B	2.09
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	29.43M

Technical Indicators

50-Day SMA	$0.30
200-Day SMA	$0.33
RSI (14)	0.00
Beta	-0.19
52-Week High	$0.42
52-Week Low	$0.24

Volume Today	2.87K
Avg Daily Volume (30D)	864
Relative Volume	3.32x
Volatility (10D)	44.18
Volatility (30D)	37.97
Free Float	12.31%

Analyst Consensus

N/A

Current Price $0.25

Mean Target N/A

52W Low$0.24 52W High$0.42

Current

Target

$0.24 $0.42

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG0058374N2

ISINAU0000327769

CountryAustralia

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Cambium Bio Limited is an Australia-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The Company’s lead product candidate, Elate Ocular, is being developed to address significant unmet medical needs in the treatment of dry eye disease. It contains enriched levels of regenerative factors, protease inhibitors, minerals and vitamins. In addition, the Company's stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. It is also developing Sygenus, a preclinical secretome-based biologic for wound healing.